Identification

Name
Butriptyline
Accession Number
DB09016
Type
Small Molecule
Groups
Approved
Description

Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.

Structure
Thumb
Synonyms
  • (±)-3-(10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-yl)-N,N,2-trimethylpropan-1-amine
External IDs
AY 62014 / AY-62014 / AY62014
Product Ingredients
IngredientUNIICASInChI Key
Butriptyline HClLIJ2H8658W5585-73-9MCWAFEJHLHEFOD-UHFFFAOYSA-N
International/Other Brands
Centrolese / Evadene / Evadyne / Evasidol
Categories
UNII
Z22441975X
CAS number
35941-65-2
Weight
Average:
Monoisotopic:
Chemical Formula
Not Available
InChI Key
Not Available
InChI
IUPAC Name
dimethyl(2-methyl-3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)amine
SMILES

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
ASodium-dependent serotonin transporter
antagonist
inhibitor
Human
AHistamine H1 receptor
antagonist
Human
A5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Side effects of tricyclic antidepressants include dry mouth, sour or metallic taste, constipation, retention of urine, blurred vision and changes in focusing, palpitations, and fast heart beat. Gastrointestinal disturbances (including nausea and vomiting), drowsiness, tremor, low blood pressure when standing, dizziness, sweating, weakness and fatigue, incoordination, epilepsy-like seizures, and speech difficulties may occur.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Butriptyline can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Butriptyline can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineButriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineButriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Butriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineButriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Butriptyline can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineButriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineButriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Butriptyline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Abediterol.Investigational
AcenocoumarolButriptyline may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AgmatineButriptyline may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AlogliptinThe serum concentration of Butriptyline can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Butriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AltretamineAltretamine may increase the orthostatic hypotensive activities of Butriptyline.Approved
AmitrazButriptyline may decrease the antihypertensive activities of Amitraz.Vet Approved
AmobarbitalThe metabolism of Butriptyline can be increased when combined with Amobarbital.Approved, Illicit
AmphetamineAmphetamine may increase the serotonergic activities of Butriptyline.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Butriptyline can be increased when it is combined with Amprenavir.Approved, Investigational
Antithrombin III humanThe serum concentration of Butriptyline can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Butriptyline can be increased when it is combined with Apixaban.Approved
ApomorphineButriptyline may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineButriptyline may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Butriptyline can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Butriptyline can be increased when it is combined with Argatroban.Approved, Investigational
AsunaprevirThe serum concentration of Butriptyline can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Butriptyline can be increased when it is combined with Atazanavir.Approved, Investigational
BambuterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Butriptyline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Butriptyline can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Butriptyline can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Butriptyline can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Butriptyline.Withdrawn
BenzamidineThe serum concentration of Butriptyline can be increased when it is combined with Benzamidine.Experimental
BenzphetamineButriptyline may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzylpenicilloyl PolylysineButriptyline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Butriptyline.Approved, Investigational
BethanidineButriptyline may decrease the antihypertensive activities of Bethanidine.Approved
BitolterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Bitolterol.Withdrawn
BivalirudinThe serum concentration of Butriptyline can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Butriptyline can be increased when it is combined with Boceprevir.Approved, Withdrawn
BrimonidineButriptyline may decrease the antihypertensive activities of Brimonidine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Butriptyline.Experimental
BromocriptineButriptyline may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BupropionThe metabolism of Butriptyline can be decreased when combined with Bupropion.Approved
CamostatThe serum concentration of Butriptyline can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Butriptyline can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Butriptyline can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Butriptyline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Butriptyline can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Butriptyline.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Butriptyline is combined with Celiprolol.Approved, Investigational
ChlorphentermineButriptyline may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChymostatinThe serum concentration of Butriptyline can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Butriptyline can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Butriptyline can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Butriptyline can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Butriptyline can be increased when it is combined with Cinacalcet.Approved
CirazolineButriptyline may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Butriptyline is combined with Citalopram.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClonidineButriptyline may decrease the antihypertensive activities of Clonidine.Approved
ClorindioneButriptyline may increase the anticoagulant activities of Clorindione.Experimental
Dabigatran etexilateThe serum concentration of Butriptyline can be increased when it is combined with Dabigatran etexilate.Approved
DarexabanThe serum concentration of Butriptyline can be increased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Butriptyline can be increased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Butriptyline can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Butriptyline can be increased when it is combined with Delapril.Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Butriptyline is combined with Desmopressin.Approved
DetomidineButriptyline may decrease the antihypertensive activities of Detomidine.Vet Approved
DexmedetomidineButriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Butriptyline.Approved, Investigational
DextroamphetamineButriptyline may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DicoumarolButriptyline may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionButriptyline may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineButriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved, Investigational
DiphenadioneButriptyline may increase the anticoagulant activities of Diphenadione.Experimental
DipivefrinButriptyline may decrease the antihypertensive activities of Dipivefrin.Approved
DL-MethylephedrineButriptyline may decrease the antihypertensive activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Dobutamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Doxofylline.Approved, Investigational
DroxidopaButriptyline may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Butriptyline.Approved
EcabetThe serum concentration of Butriptyline can be increased when it is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Butriptyline can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Butriptyline can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Butriptyline can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Butriptyline can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Butriptyline can be increased when it is combined with Enalkiren.Experimental
EphedraButriptyline may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineButriptyline may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovineButriptyline may increase the vasopressor activities of Ergonovine.Approved
ErgotamineButriptyline may decrease the antihypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Butriptyline is combined with Escitalopram.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Etafedrine.Approved
Ethyl biscoumacetateButriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateButriptyline may decrease the antihypertensive activities of Etomidate.Approved
FaldaprevirThe serum concentration of Butriptyline can be increased when it is combined with Faldaprevir.Investigational
FenoterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Fenoterol.Approved, Investigational
FluindioneButriptyline may increase the anticoagulant activities of Fluindione.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Butriptyline.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butriptyline.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Butriptyline can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Butriptyline can be increased when it is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the serotonergic activities of Butriptyline.Approved, Investigational, Vet Approved
GabexateThe serum concentration of Butriptyline can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Butriptyline can be increased when it is combined with Geldanamycin.Experimental, Investigational
GepefrineButriptyline may increase the stimulatory activities of Gepefrine.Experimental
GM6001The serum concentration of Butriptyline can be increased when it is combined with GM6001.Experimental
GuanabenzButriptyline may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineButriptyline may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HarmalineHarmaline may increase the serotonergic activities of Butriptyline.Experimental
HexobarbitalThe metabolism of Butriptyline can be increased when combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Hexoprenaline.Approved, Withdrawn
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Butriptyline.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Butriptyline.Experimental
HydroxyamphetamineButriptyline may increase the stimulatory activities of Hydroxyamphetamine.Approved
IdraparinuxThe serum concentration of Butriptyline can be increased when it is combined with Idraparinux.Investigational
ImidaprilThe serum concentration of Butriptyline can be increased when it is combined with Imidapril.Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Indacaterol.Approved
IndinavirThe serum concentration of Butriptyline can be increased when it is combined with Indinavir.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Butriptyline.Approved, Investigational
Iofetamine I-123Butriptyline may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Butriptyline.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Butriptyline.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Butriptyline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Isoetarine.Approved
IsoflurophateThe serum concentration of Butriptyline can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneButriptyline may increase the vasopressor activities of Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Isoprenaline.Approved, Investigational
IxazomibThe serum concentration of Butriptyline can be increased when it is combined with Ixazomib.Approved, Investigational
LepirudinThe serum concentration of Butriptyline can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Butriptyline can be increased when it is combined with Letaxaban.Investigational
LevonordefrinButriptyline may decrease the antihypertensive activities of Levonordefrin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Levosalbutamol.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Butriptyline.Approved
LinagliptinThe serum concentration of Butriptyline can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Butriptyline.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Butriptyline.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Butriptyline.Approved
LisdexamfetamineButriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Butriptyline can be increased when it is combined with Lisinopril.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Butriptyline.Experimental
LofexidineButriptyline may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Butriptyline can be increased when it is combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Butriptyline can be increased when it is combined with Lorpiprazole.Approved
MebanazineMebanazine may increase the serotonergic activities of Butriptyline.Withdrawn
MedetomidineButriptyline may decrease the antihypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Butriptyline can be increased when it is combined with Melagatran.Experimental
MephedroneButriptyline may increase the stimulatory activities of Mephedrone.Investigational
MephentermineButriptyline may increase the vasopressor activities of Mephentermine.Approved
MetaraminolButriptyline may increase the vasopressor activities of Metaraminol.Approved, Investigational
MethamphetamineButriptyline may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethohexitalThe metabolism of Butriptyline can be increased when combined with Methohexital.Approved
MethoxamineButriptyline may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyphenamineButriptyline may increase the stimulatory activities of Methoxyphenamine.Experimental
MethyldopaButriptyline may decrease the antihypertensive activities of Methyldopa.Approved
Methylene blueButriptyline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Butriptyline.Approved, Investigational
MethylphenobarbitalThe metabolism of Butriptyline can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Butriptyline.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Butriptyline.Approved
MidodrineButriptyline may increase the vasopressor activities of Midodrine.Approved
MidomafetamineButriptyline may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MinaprineMinaprine may increase the serotonergic activities of Butriptyline.Approved
MMDAButriptyline may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Butriptyline.Approved, Investigational
MoexiprilThe serum concentration of Butriptyline can be increased when it is combined with Moexipril.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Butriptyline.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Butriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NafamostatThe serum concentration of Butriptyline can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineButriptyline may decrease the antihypertensive activities of Naphazoline.Approved
NelfinavirThe serum concentration of Butriptyline can be increased when it is combined with Nelfinavir.Approved
NialamideNialamide may increase the serotonergic activities of Butriptyline.Withdrawn
NicorandilButriptyline may increase the hypotensive activities of Nicorandil.Approved, Investigational
NorepinephrineButriptyline may decrease the antihypertensive activities of Norepinephrine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Butriptyline.Withdrawn
OlodaterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Olodaterol.Approved
OmapatrilatThe serum concentration of Butriptyline can be increased when it is combined with Omapatrilat.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Orciprenaline.Approved
OtamixabanThe serum concentration of Butriptyline can be increased when it is combined with Otamixaban.Investigational
OxymetazolineButriptyline may decrease the antihypertensive activities of Oxymetazoline.Approved, Investigational
PaliperidoneButriptyline may decrease the antihypertensive activities of Paliperidone.Approved
PargylinePargyline may increase the serotonergic activities of Butriptyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Butriptyline.Approved, Investigational
PentobarbitalThe metabolism of Butriptyline can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideButriptyline may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Butriptyline can be increased when it is combined with Perindopril.Approved
PF-00610355The risk or severity of adverse effects can be increased when Butriptyline is combined with PF-00610355.Investigational
PhendimetrazineButriptyline may increase the vasopressor activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Butriptyline.Approved
PhenindioneButriptyline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Butriptyline.Withdrawn
PhenobarbitalThe metabolism of Butriptyline can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Butriptyline.Withdrawn
PhenprocoumonButriptyline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineButriptyline may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineButriptyline may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhosphoramidonThe serum concentration of Butriptyline can be increased when it is combined with Phosphoramidon.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Pirbuterol.Approved
PirlindolePirlindole may increase the serotonergic activities of Butriptyline.Approved
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Butriptyline.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Butriptyline.Withdrawn
PrimidoneThe metabolism of Butriptyline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Butriptyline can be increased when it is combined with Prinomastat.Investigational
ProcaineProcaine may increase the serotonergic activities of Butriptyline.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Butriptyline.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Procaterol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Protokylol.Approved, Vet Approved
PseudoephedrineButriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuinaprilThe serum concentration of Butriptyline can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineButriptyline may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
RacecadotrilThe serum concentration of Butriptyline can be increased when it is combined with Racecadotril.Investigational
RacepinephrineButriptyline may decrease the antihypertensive activities of Racepinephrine.Approved
RamiprilThe serum concentration of Butriptyline can be increased when it is combined with Ramipril.Approved
RasagilineRasagiline may increase the serotonergic activities of Butriptyline.Approved
RemikirenThe serum concentration of Butriptyline can be increased when it is combined with Remikiren.Approved
RisperidoneButriptyline may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitobegronButriptyline may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Butriptyline can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Butriptyline can be increased when it is combined with Rivaroxaban.Approved
RomifidineButriptyline may decrease the antihypertensive activities of Romifidine.Vet Approved
RopiniroleButriptyline may decrease the antihypertensive activities of Ropinirole.Approved, Investigational
S-3304The serum concentration of Butriptyline can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Butriptyline.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Butriptyline can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Butriptyline can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Butriptyline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Butriptyline.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Butriptyline.Approved
SimeprevirThe serum concentration of Butriptyline can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Butriptyline can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Butriptyline can be increased when it is combined with Sivelestat.Investigational
Sodium phosphate, monobasicThe risk or severity of adverse effects can be increased when Butriptyline is combined with Sodium phosphate.Approved
SpiraprilThe serum concentration of Butriptyline can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Butriptyline can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
TelaprevirThe serum concentration of Butriptyline can be increased when it is combined with Telaprevir.Approved, Withdrawn
TemocaprilThe serum concentration of Butriptyline can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Butriptyline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Terbutaline.Approved
TetryzolineButriptyline may increase the vasopressor activities of Tetryzoline.Approved
ThiamylalThe metabolism of Butriptyline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Butriptyline can be increased when combined with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Butriptyline can be increased when it is combined with Thiorphan.Experimental
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Butriptyline.Approved
TioclomarolButriptyline may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Butriptyline can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineButriptyline may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
ToloxatoneToloxatone may increase the serotonergic activities of Butriptyline.Approved
TramadolButriptyline may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Butriptyline can be increased when it is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the serotonergic activities of Butriptyline.Approved, Investigational
UbenimexThe serum concentration of Butriptyline can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Butriptyline can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Butriptyline can be increased when it is combined with Valproic Acid.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Butriptyline.Approved
VilanterolThe risk or severity of adverse effects can be increased when Butriptyline is combined with Vilanterol.Approved
VildagliptinThe serum concentration of Butriptyline can be increased when it is combined with Vildagliptin.Approved, Investigational
WarfarinButriptyline may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Butriptyline can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineButriptyline may decrease the antihypertensive activities of Xylazine.Vet Approved
XylometazolineButriptyline may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Butriptyline.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Butriptyline can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZofenoprilThe serum concentration of Butriptyline can be increased when it is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,409,640.

General References
Not Available
External Links
KEGG Drug
D07601
PubChem Compound
21772
PubChem Substance
347910390
ChEMBL
CHEMBL2110816
Wikipedia
Butriptyline
ATC Codes
N06AA15 — Butriptyline
MSDS
Download (306 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP5.44ChemAxon
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.95 m3·mol-1ChemAxon
Polarizability35.53 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Aralkylamines / Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzocycloheptene / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  2. Wander TJ, Nelson A, Okazaki H, Richelson E: Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol. 1986 Dec 16;132(2-3):115-21. [PubMed:3816971]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  2. Wander TJ, Nelson A, Okazaki H, Richelson E: Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol. 1986 Dec 16;132(2-3):115-21. [PubMed:3816971]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
  2. Wander TJ, Nelson A, Okazaki H, Richelson E: Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur J Pharmacol. 1986 Dec 16;132(2-3):115-21. [PubMed:3816971]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]

Drug created on June 23, 2014 12:40 / Updated on July 02, 2018 20:41